⌕
uniQure · QURE · Nasdaq
Tenet 37 · Weak
Compare
$20.78−5.03%At closeTenet 37 · Weak
$20.78−1.10 (−5.03%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

uniQure (QURE) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is QURE's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● Seeking AlphaNov 14, 2026 · 01:38 ET
uniQure: A Breakthrough In Huntington's, With A Market Too Large To Ignore

The FDA reversed its support for natural-history controls, demanded a sham-controlled trial, then reversed course again, delaying progress for months while Huntington's patients continued suffering irreversible decline. …

QURE −5.0% todayRead at source ↗
● MarketBeatNov 13, 2026 · 18:13 ET
uniQure CEO Defends Huntington's Therapy Data, Sees Opportunity Ahead of FDA Decision

uniQure NASDAQ: QURE Chief Executive Matt Kapusta said investors are focused on regulatory risk surrounding its experimental Huntington's disease therapy, AMT-130, but may be underestimating the need for treatment and th…

QURE −5.0% todayRead at source ↗
● Zacks Investment ResearchNov 13, 2026 · 14:21 ET
QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?

uniQure shares rally 17.5% as FDA grants Priority Review to its Huntington's disease gene therapy, but it remains to be seen if clinical and regulatory progress can sustain momentum.…

QURE −5.0% todayRead at source ↗
● MarketBeatNov 13, 2026 · 07:15 ET
uniQure Prepares for Potential FDA Panel on Huntington's Gene Therapy After Priority Review Nod

uniQure NASDAQ: QURE is preparing for a potential U.S. advisory committee meeting on AMT-130, its experimental gene therapy for Huntington's disease, after regulators accepted its biologics license application for priori…

QURE −5.0% todayRead at source ↗
● MarketBeatNov 4, 2026 · 14:15 ET
uniQure Q3 Earnings Call Highlights

uniQure NASDAQ: QURE said the FDA has accepted its Biologics License Application for AMT-130, an investigational treatment for Huntington's disease, and granted the application Priority Review with a target action date o…

QURE −5.0% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 14:04 ET
uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript

uniQure N.V. (QURE) Q3 2026 Earnings Call Transcript…

QURE −5.0% todayRead at source ↗
● Zacks Investment ResearchNov 4, 2026 · 09:56 ET
uniQure (QURE) Reports Q3 Loss, Misses Revenue Estimates

uniQure (QURE) came out with a quarterly loss of $0.88 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to a loss of $1.38 per share a year ago.…

QURE −5.0% todayRead at source ↗
● GlobeNewsWireNov 4, 2026 · 07:05 ETCOMPANY'S OWN WORDS
uniQure Announces Third Quarter 2026 Financial Results and Provides Company Update

~ FDA granted priority review of BLA for  ifezuntirgene inilparvovec (AMT-130) in Huntington's disease; PDUFA target action date of May 1, 2027 ~…

QURE −5.0% todayRead at source ↗
● Seeking AlphaNov 4, 2026 · 01:46 ET
uniQure: The Market May Be Misreading The AMT-130 Four-Year Data (Rating Upgrade)

uniQure's stock has come under significant pressure again after the company reported mixed 4-year AMT-130 data. While measurement noise and control bias likely explain much of the disappointing results, there is now grea…

QURE −5.0% todayRead at source ↗
● BenzingaNov 2, 2026 · 11:55 ET
FDA Pushes uniQure Huntington Therapy Forward, Analyst Brushes Off Softening Signals

The U.S. Food and Drug Administration has accepted uniQure NV's (NASDAQ:QURE) Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for Huntington's disease submitted under t…

QURE −5.0% todayRead at source ↗
● GlobeNewsWireNov 2, 2026 · 07:05 ETCOMPANY'S OWN WORDS
uniQure Announces FDA Acceptance and Priority Review of the Biologics License Application for ifezuntirgene inilparvovec for the Treatment of Huntington's Disease

~ FDA sets PDUFA target action date of May 1, 2027 ~ ~ If approved, ifezuntirgene inilparvovec will be the world's first disease-modifying treatment for Huntington's disease ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 202…

QURE −5.0% todayRead at source ↗
● Zacks Investment ResearchOct 30, 2026 · 11:11 ET
3 Promising Genomics Stocks to Add to Your Portfolio Now

Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.…

QURE −5.0% todayRead at source ↗
● GlobeNewsWireOct 28, 2026 · 07:05 ETCOMPANY'S OWN WORDS
uniQure to Announce Third Quarter 2026 Financial Results

~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~ ~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~…

QURE −5.0% todayRead at source ↗
● Seeking AlphaOct 15, 2026 · 10:24 ET
uniQure: The Market Graded The Wrong Exam

uniQure (QURE) is rated a Speculative Buy with a $47 price target, implying 115% upside. QURE's Huntington's gene therapy BLA is under FDA accelerated review, with a decision expected around November 1. Three-year data m…

QURE −5.0% todayRead at source ↗
● Newsfile CorpOct 13, 2026 · 19:11 ET
uniQure N.V. Investigation Continues: Investors May Contact Kirby McInerney LLP, a Securities Fraud Law Firm, If You Lost Money On Your QURE Investments

New York, New York--(Newsfile Corp. - October 13, 2026) - The law firm of Kirby McInerney LLP continues its investigation on behalf of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE) investors concerning the Com…

QURE −5.0% todayRead at source ↗
● Defense WorldOct 8, 2026 · 04:15 ET
uniQure (NASDAQ:QURE) and Vir Biotechnology (NASDAQ:VIR) Critical Review

Vir Biotechnology (NASDAQ: VIR - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the stre…

QURE −5.0% todayRead at source ↗
● Seeking AlphaOct 7, 2026 · 15:48 ET
Cedar Grove Capital Q3 2026 Portfolio Update

During the quarter, we closed our long positions in MTY Food Group, uniQure, ClearPoint Neuro, and Suja Life Inc. During the quarter, we closed short positions in Bending Spoons SpA, Chipotle Mexican Grill, The Ensign Gr…

QURE −5.0% todayRead at source ↗
● Business WireOct 6, 2026 · 18:00 ET
UNIQURE N.V. QURE INVESTORS: Contact Kirby McInerney LLP About the Firm's Securities Investigation Following 37.3% Share Drop

NEW YORK--(BUSINESS WIRE)---- $QURE #ClassActionLawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE) investors concerni…

QURE −5.0% todayRead at source ↗
● Defense WorldOct 6, 2026 · 10:20 ET
uniQure (NASDAQ:QURE) Stock Price Down 5.5% Following Analyst Downgrade

uniQure N.V. (NASDAQ: QURE - Get Free Report)'s share price was down 5.5% on Tuesday after Barclays downgraded the stock from an overweight rating to an equal weight rating. Barclays now has a $28.00 price target on the …

QURE −5.0% todayRead at source ↗
● Defense WorldOct 6, 2026 · 08:14 ET
Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)

Alkermes (NASDAQ: ALKS - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their anal…

QURE −5.0% todayRead at source ↗
● Defense WorldOct 5, 2026 · 10:20 ET
uniQure (NASDAQ:QURE) Shares Gap Down on Analyst Downgrade

Shares of uniQure N.V. (NASDAQ: QURE - Get Free Report) gapped down prior to trading on Monday after Barclays downgraded the stock from an overweight rating to an equal weight rating. The stock had previously closed at $…

QURE −5.0% todayRead at source ↗
● GlobeNewsWireSep 30, 2026 · 18:43 ET
UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ: QURE). The investigation concerns whether the …

QURE −5.0% todayRead at source ↗
● Zacks Investment ResearchSep 30, 2026 · 14:50 ET
uniQure Plunges on Additional Data From Huntington's Disease Study

QURE's Huntingtons gene therapy shows sustained functional benefits at 36 months, but mixed 48-month data add uncertainty.…

QURE −5.0% todayRead at source ↗
● Seeking AlphaSep 30, 2026 · 13:17 ET
uniQure: A Speculative Buy After Huntington's Disease Trial's 4-Year Data Update

On Tuesday, Sep. 29, uniQure reported four-year AMT-130 data for Huntington's Disease that included cUHDRS & TFC four-year data. cUHDRS at year 4 showed 44% slowing, with a non-significant p=0.144. Per QURE, this may hav…

QURE −5.0% todayRead at source ↗
● PRNewsWireSep 29, 2026 · 20:12 ETCOMPANY'S OWN WORDS
uniQure Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into uniQure (QURE)

uniQure's four-year AMT-130 Huntington's disease benefit came in smaller than its three-year result, and QURE shares plummeted. SueWallSt notifies investors of a pending investigation into potential securities law violat…

QURE −5.0% todayRead at source ↗
● Business WireSep 29, 2026 · 13:28 ET
QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law

LOS ANGELES--(BUSINESS WIRE)---- $QURE--QURE Investors Have Opportunity to Join uniQure N.V. Fraud Investigation with SBS Law.…

QURE −5.0% todayRead at source ↗
● GlobeNewsWireSep 29, 2026 · 11:00 ET
QURE Investor Alert: uniQure Securities Investigation - Kehoe Law Firm, P.C.

PHILADELPHIA, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C.…

QURE −5.0% todayRead at source ↗
● GlobeNewsWireSep 29, 2026 · 07:12 ETCOMPANY'S OWN WORDS
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's Disease Showing Continued Slowing of Disease Progression

~ In 12 high-dose patients at 48 months, both cUHDRS and TFC continued to demonstrate meaningful slowing of disease progression and clear dose-dependent response; the primary endpoint of cUHDRS showed 44% slowing of dise…

QURE −5.0% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA29−0.4%
WDAY4−5.8%
BBW3−2.6%

Article counts from the last market-wide feed page, across every symbol we track and not just QURE · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.